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Correspondence, case report 
Background 
The effects of extra corporal membrane oxygenation (ECMO) on pharmacokinetics (PK) of drugs is 
difficult to predict. Generally, an increased volume of distribution, decreased drug elimination, and 
sequestration of the drug to the ECMO circuit are factors potentially influencing the PK of drugs 
during ECMO.[1, 2] Zidovudine is the only antiretroviral agent suitable for intravenous use in 
newborns for the prevention of perinatal HIV transmission. No reported cases of the influence of 
ECMO on the PK of zidovudine in prematures were found. We describe the first PK data in a 
premature neonate requiring intravenous zidovudine while on ECMO. 
 
Case presentation 
A premature child (gestational age 32 weeks) born from a virologically suppressed HIV infected 
mother required ECMO to undergo the resection of an intrathoracic lesion compromising the lungs. 
IV zidovudine was administered for the prevention of HIV transmission as per standard guidelines.  
To cope with the anticipated increased volume of distribution (Vd) and in order to avoid the risks 
caused by under treatment, IV zidovudine was dosed 9mg/kg/day (150% of the dose normally used 
in premature infants) for the duration of ECMO. Plasma samples were taken before, during and after 
ECMO. Samples were analysed using LC-MS technology. Therapeutic drug monitoring (TDM) was 
used to observe treatment and PK parameters were calculated using non-compartmental analysis in 
WinNonlin. Parents consented to the presentation of these data. 
With clearance 0.62 L/h, Vd 3.3 L, and t½ of 3.6 h, zidovudine concentrations remained above 0.8mg/L 
during ECMO (Figure 1). While pharmacokinetic reports on prematures are highly variable with no 
Ctroughs or AUCs reported, these PK parameters suggest slow clearance of zidovudine, leading to a 
degree of exposure that has been correlated to increased safety risks in earlier studies.[3] No adverse 
events were reported in this case and zidovudine levels returned to normal on standard doses after 
ECMO cessation.[4, 5] The HIV proviral DNA PCR in the child was negative at 3 months of age. 
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Learning Points/Discussion 
It might be difficult to tease out the influence of ECMO versus the premature age on the PK of 
zidovudine in this particular child. However, the fact that, after ECMO PK parameters of zidovudine 
were normal after administering normal doses while they were higher during ECMO at a higher dose 
of zidovudine, suggests that ECMO does not have a major impact on zidovudine PK. Therefore, we 
recommend that in future occasions, standard IV dosing of zidovudine in premature children on 
ECMO is recommended under the guidance of TDM. 
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Figure legend 
 Figure 1. Zidovudine (AZT) levels post dosing 
●  Zidovudine levels with iv medication, no ECMO 
□  Zidovudine levels with iv medication on ECMO 
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